Skip to main content
Signal8
Launch Terminal

4D Molecular Therapeutics, Inc. (FDMT)

4D Molecular Therapeutics, Inc. is a clinical-stage gene therapy company that engineers therapeutic agents by leveraging its proprietary adeno-associated virus (AAV) vector technology. The company's developmental efforts are concentrated across a trio of therapeutic fields: ophthalmology (eye conditions), cardiology (heart ailments), and pulmonology (respiratory disorders). Within its active pipeline, three specific product candidates have advanced into clinical trial phases, all currently undergoing Phase 1/2 clinical assessment: 4D-125 is being evaluated for the treatment of X-linked retinitis pigmentosa. 4D-110 targets choroideremia. 4D-310 is focused on addressing Fabry disease. Beyond these, two Investigational New Drug (IND) candidates are in development: 4D-150, aimed at combating wet age-related macular degeneration, and 4D-710, designed to tackle cystic fibrosis lung disease. To advance its mission, 4D Molecular Therapeutics, Inc. actively engages in research and development partnerships with entities such as uniQure, CRF, Roche, and CFF. The firm commenced operations in 2013 and maintains its headquarters in Emeryville, California.

Sector: Biological Products, (No Diagnostic Substances)

Industry: Biotechnology

4D Molecular Therapeutics, Inc. logo

4D Molecular Therapeutics, Inc.

NASDAQ:FDMTHealthcare
-6.89%$11.90
AH$11.90+0.00%vs close
Mkt Cap$657.41M
Float53.34M
O/S55.24M
Vol
$ Vol
RVOL
Inst Own-
SI21.6%
Earnings
Dilution
4D Molecular Therapeutics, Inc. logoNASDAQ:FDMT$11.90-6.89%
Phase Distribution
11 lead-sponsored trials·10 active·0 completed
Phase 11
Phase 1/24
Phase 22
Phase 33
Not applicable1
Status Overview
Recruiting5
Active, not recruiting5
Stopped1

Trials need funding. See this company's dilution risk and cash position.

Clinical Trials
Status
Phase
  • Phase 3
    Active, not recruiting

    4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration

    4D-150 IVT (3E10 vg/eye), EYLEA® (aflibercept) Injection 2 mg (0.05mL)

    Macular Neovascularization Secondary to Age-Related Macular Degeneration

    Enrollment
    480
    Start
    Mar 2025
    Primary Completion
    Jun 2027est.
    Completion
    Jun 2028est.
    NCT06864988
  • Phase 3
    Recruiting

    Single Intravitreal (IVT) Injection of 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration

    4D-150 IVT (3E10 vg/eye), EYLEA® (aflibercept) Injection 2 mg (0.05mL)

    Neovascular Age-Related Macular Degeneration (nAMD)

    Enrollment
    480
    Start
    Jul 2025
    Primary Completion
    Nov 2027est.
    Completion
    Nov 2029est.
    NCT07064759
  • Phase 3
    Recruiting

    A Phase 3 Trial for Intravitreal Injection of 4D-150 in Adults With Diabetic Macular Edema (DME).

    4D-150 IVT (3x10^10 vg), EYELEA ® (aflibercept) Injection 2 mg (0.05mL)

    Diabetic Macular Edema (DME)

    Enrollment
    514
    Start
    Sep 2026
    Primary Completion
    Jan 2029est.
    Completion
    Jan 2030est.
    NCT07867080
  • Phase 2
    Recruiting

    4D-710 in Adult Patients With Cystic Fibrosis

    4D-710

    Cystic Fibrosis Lung

    Enrollment
    30
    Start
    Mar 2022
    Primary Completion
    Jun 2027est.
    Completion
    Jun 2031est.
    NCT05248230
  • Phase 2
    Active, not recruiting

    4D-150 in Patients With Diabetic Macular Edema

    4D-150 IVT, Aflibercept IVT

    Diabetic Macular Edema, Diabetic Retinopathy

    Enrollment
    72
    Start
    Aug 2023
    Primary Completion
    Feb 2029est.
    Completion
    Feb 2029est.
    NCT05930561
  • Phase 1/2
    Active, not recruiting

    4D-125 in Patients With X-Linked Retinitis Pigmentosa (XLRP)

    4D-125 IVT Injection

    X-Linked Retinitis Pigmentosa

    Enrollment
    21
    Start
    Jun 2020
    Primary Completion
    Jun 2026est.
    Completion
    May 2029est.
    NCT04517149
  • Phase 1/2
    Active, not recruiting

    An Open-label, Phase 1/2 Trial of Gene Therapy 4D-310 in Adults With Fabry Disease

    4D-310

    Fabry Disease

    Enrollment
    18
    Start
    Sep 2020
    Primary Completion
    Jan 2026est.
    Completion
    Jun 2030est.
    NCT04519749
  • Phase 1/2
    Recruiting

    4D-150 in Patients With Neovascular (Wet) Age-Related Macular Degeneration

    4D-150 IVT, Aflibercept IVT

    Neovascular (Wet) Age-Related Macular Degeneration

    Enrollment
    215
    Start
    Dec 2021
    Primary Completion
    Mar 2027est.
    Completion
    Jan 2031est.
    NCT05197270
  • Phase 1/2
    Recruiting

    4D-310 in Adults With Fabry Disease and Cardiac Involvement

    4D-310

    Fabry Disease

    Enrollment
    18
    Start
    Oct 2022
    Primary Completion
    Jun 2026est.
    Completion
    Jun 2030est.
    NCT05629559
  • Phase 1
    Active, not recruiting

    Dose Escalation Study of Intravitreal 4D-110 in Patients With Choroideremia

    4D-110

    Choroideremia

    Enrollment
    13
    Start
    Jun 2020
    Primary Completion
    May 2027est.
    Completion
    Aug 2027est.
    NCT04483440
  • Observational
    Terminated

    "Natural History" Study of Choroideremia

    Observation

    Choroideremia

    Enrollment
    57
    Start
    Dec 2016
    Primary Completion
    Oct 2021
    Completion
    Oct 2021
    NCT02994368
Search ClinicalTrials.gov for “4D Molecular Therapeutics”